efavirenz, emtricitabine and tenofovir disoproxil fumarate
efavirenz, emtricitabine and tenofovir disoproxil fumarate is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including efavirenz, emtricitabine and tenofovir disoproxil fumarate. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- efavirenz, emtricitabine and tenofovir disoproxil fumarate
- Brand Names
- efavirenz, emtricitabine and tenofovir disoproxil fumarate
- Application Number
- ANDA206894
- Sponsor
- Cipla USA Inc.
- NDC Codes
- 1
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE
Indications and Usage
1 INDICATIONS AND USAGE Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet is a three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. (1)